Drugs

Dapagliflozin (Farxiga) in Patients with Chronic Kidney Disease

Many patients with chronic kidney disease are at a higher risk for severe kidney and heart health issues. The DAPA-CKD trial was designed to see the impact of Dapagliflozin Propanediol, which is sold under the brand name Farxiga, in patients with and without type 2 diabetes who had chronic kidney disease. Read more

Access to SGLT-2 Medications Varies by Gender, Ethnicity

A recent study says that the access of people with type 2 diabetes to sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment has significant ethnic, gender and socioeconomic disparities, with women, Black or Asian patients less likely to receive SGLT-2 inhibitor treatment. Read more

Metformin and Kidney Function

The widely used type 2 diabetes drug metformin is often associated with lactic acidosis, especially in patients with kidney disease. However, a new study suggests this may not the case for patients with mild to moderate kidney disease. Read more

Benefits of Canagliflozin for Heart Disease

A study of the diabetes drug canagliflozin (Invokana) found that it was able to steadily reduce the risk of death and hospitalizations due to heart failure in patients with both type 2 diabetes and chronic kidney disease. Read more

FDA Gives Breakthrough Designation to Type 1 Drug

The U.S. Food and Drug Administration (FDA) grants its Breakthrough Therapy designation to new drugs that show promise, to speed up the drugs’ development and review. A new type 1 diabetes drug, vTv Therapeutics’ TTP399, which is being developed as an adjunctive therapy to insulin for type 1 diabetes, has been granted this designation. Read […]

Guide to Heart Impacts of Newer Diabetes Drugs

A recently published expert overview examines the cardiovascular benefits and risks of common diabetes drugs currently available in the United States, and lists which newer drug classes are beneficial for diabetes patients who already have indications of heart or blood vessel disease. Read more

Class of Diabetes Drug May Help Anemia

SGLT-2 inhibitors, a diabetes drug class that includes drugs like canagliflozin (Invokana) have been shown to be beneficial for patients who have both type 2 diabetes and chronic kidney disease in regards to developing anemia. Read more

Tirzepatide Shows Benefits in Type 2 Patients

Tirzepatide, a newer diabetes drug, has been shown to reduce patient hemoglobin A1c levels, as well as lowering body weight and improving insulin sensitivity markers in patients with type 2 diabetes.  Read more

Can Some Drugs that Lower Glucose Also Treat COVID-19?

Some drugs used to lower glucose in patients with diabetes, such as metformin, SGLT2 inhibitors, and sulfonylureas, might have beneficial effects on COVID-19, potentially affecting the risk of progression to severe disease and death. Read more

Sotagliflozin + Insulin for Type 1 Diabetes

SGLT-2 inhibitors like sotagliflozin are antihyperglycemic agents approved in the US for use in patients with type 2 diabetes. However, sotagliflozin is also approved for type 1 diabetes in Europe, and studies have shown that using sotagliflozin along with insulin has benefits in patients with type 1 diabetes. Read more

The “Medication Burden” and Type 2 Diabetes

People who have type 2 diabetes are likely to have complicated medication regimens that involve taking multiple drugs (also known as polypharmacy). Complex medication regimens are associated with worse health outcomes, as it is more difficult to follow a complicated treatment correctly, and there is increased risk for drug interactions. Read more

Researchers Seek Potential New Obesity & Type 2 Drug

GIP and GLP-1 are substances produced in the body’s digestive tract, and they play important roles in regulating body weight and food intake. A recently published study on their effects suggests that they may one day be used to develop drugs to treat obesity and type 2 diabetes. Read more

Diabetes Med May Treat Parkinson’s Disease

A clinical trial is being conducted in the United Kingdom to investigate whether the diabetes drug exenatide (Byetta) can be used to treat Parkinson’s Disease. Previous research has found that the risk for Parkinson’s is reduced in people who are treated with exenatide for their type 2 diabetes. Read more

Metformin Can Improve Surgical Recovery

Metformin, a commonly-prescribed diabetes drug, may have other benefits, researchers say. A study found that metformin use in patients with type 2 diabetes is associated with a reduced risk of rehospitalization and death following surgery. Read more

Start Combination Therapy Earlier, ADA Says

Metformin is the typical first-line treatment for people with type 2 diabetes, but the ADA suggests early combination therapy with other medications should be used in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease. Read more

More Evidence for Heart Benefits of Empagliflozin

Studies of diabetes drugs empagliflozin and dapagliflozin, both in the SGLT-2 inhibitor class, have shown they help reduce cardiovascular risk for diabetes patients. Now, researchers have found that empagliflozin is beneficial for the heart in people without diabetes as well. Read more

Once-Weekly Semaglutide May Assist with Weight Loss

The diabetes drug semaglutide, administered once-weekly subcutaneously and used in conjunction with lifestyle modifications, helped people with overweight or obesity achieve sustained, significant reductions in body weight. Read more

Diabetes Pharma Company Seeks to Reach More Young People with Type 1

Eli Lilly is expanding its existing type 1 diabetes partnership with Life for a Child, with the goal of supporting more than six times as many children in the next 10 years. Lilly plans to expand care to 150,000 young people with diabetes over the next decade, providing free medicine and equipment like reusable pens […]

Add-on Therapy Can Reduce Insulin Use for Type 2 Patients

Insulin is the mainstay treatment for patients with type 2 diabetes who also have beta-cell failure; however, some insulin regimens can be complicated to manage and may increase the risk of hypoglycemia. Now, researchers say that a simple add-on therapy with the GLP-1 Agonist medication albiglutide can reduce insulin use for patients with type 2 […]

Adding the Right Meds Early Can Reduce Heart Risks

High blood glucose levels can damage the heart’s nerves and blood vessels. This contributes to the development of heart diseases and eventual heart attacks. However, new research shows that starting patients on medication to prevent cardiovascular diseases when they are first diagnosed with diabetes can help reduce the risk. Read more